Full Text View
Tabular View
No Study Results Posted
Related Studies
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
This study has been completed.
Study NCT00079768   Information provided by National Institutes of Health Clinical Center (CC)
First Received: March 12, 2004   Last Updated: January 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myositis, Inclusion Body
Additional conditions recognized in this trial
Myositis
More general conditions related to this trial
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Interventions listed in this trial
Alemtuzumab (Campath)
Additional drug interventions recognized in this trial
Alemtuzumab
Antibodies, Monoclonal
More general drug interventions related to this trial
Antineoplastic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Institute of Neurological Disorders and Stroke (NINDS)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services